The position paper of an interdisciplinary team of experts regarding the treatment of patients with hypertension and concomitant cognitive deficits in daily medical practice Current opinion
Article Sidebar
Published:
Sep 30, 2017
Keywords:
arterial hypertension, cognitive and dementia deficits, vinpocetine
Main Article Content
Abstract
The increase in life expectancy is an unquestionable success of medicine, which brings with it an increase in the number of diseases including more cases of dementia syndromes. One of the basic, modifiable risk factors for vascular dementia is arterial hypertension, which causes changes in the cerebral microcirculation and contributes to the development of cognitive dysfunction and dementia. Appropriate, effective pharmacotherapy provides patients with proper and long-lasting cardio and neuroprotection.
Article Details
How to Cite
Mamcarz , A., Mastalerz-Migas, A., Mirowska-Guzel, D., Szulc , A., Tykarski , A., & Widecka, K. (2017). The position paper of an interdisciplinary team of experts regarding the treatment of patients with hypertension and concomitant cognitive deficits in daily medical practice. Medycyna Faktow (J EBM), 10(3(36), 183-196. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2122
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McKhann G.M., Knopman D.S., Chertkow H. et.al.: The diagnosis od dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s & Dementia 2011: 1–7.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
3. Zdrojewski T., Rutkowski M., Bandosz P. et al.: Prevalence and control of cardiovascular risk factors in Poland. Assumption and objectives of the NATPOL 2011 Survey. Kardiol. Pol. 2013; 71: 381-391.
4. Zdrojewski T., Szpakowski P., Bandosz P. et al.: Arterial hypertension in Poland in 2002. J. Hum. Hypertens. 2004; 18(8): 557-562.
5. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
6. Tykarski A., Narkiewicz K., Gaciong Z. et al.: 2015 Guidelines for the management of hypertension. Arterial Hypertens. 2015; 19 (2): 53-83.
7. Drygas W., Niklas A., Piwońska A.: Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol. Pol. 2016; 74: 681-690.
8. Ivan C.S., Seshadri S., Beiser A. et al.: Dementia after stroke: the Framingham Study. Stroke 2004; 35: 1264-1268.
9. Wong T.Y., Klein R., Sharrett A.R. et al.: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons. The Atherosclerosis Risk in Communities Study. Stroke 2002; 33: 1487-1492.
10. Vermeer S.E., Longstreth W.T. Jr, Koudstaal P.J.: Silent brain infarcts: a systematic review. Lancet Neurol. 2007; 6(7): 611-619.
11. Fang M., Feng C., Xu Y. et al.: Microbleeds and Silent Brain Infarctions Are Differently Associated with Cognitive Dysfunction in Patients with Advanced Periventricular Leukoaraiosis. Int. J. Med. Sci. 2013; 10(10): 1307-1313.
12. Prabhakaran S., Wright C.B., Yoshita M. et al.: The prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study; Neurology 2008; 70(6): 425-430.
13. Sacco R.L., Adams R., Albers G. et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
14. Baumgart M., Snyder H.M., Carrillo M.C. et al.: Summary of the evidence on modifiable risk factors for cognitive decline and dementia. A population- based perspective. Alzheimers Dement. 2015; 11: 718-726.
15. Skoog I., Lernfelt B., Landahi S. et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347(9009): 1141-1145.
16. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
17. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline does age make a difference? Hypertension 2004; 44: 631-638.
18. Cuadra A.E., Shan Z., Sumners C. et al.: A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol. Ther. 2010; 125: 27-38.
19. Xia H., Lazartigues E.: Angiotensin-converting enzyme 2: central regular for cardiovascular function. Curr. Hypertens. Rep. 2010; 12: 170-175.
20. Wright J.W., Harding J.W.: Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 1997; 25: 96-124.
21. Stragier B., DeBundel D., Sarre S. et al.: Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail. Rev. 2008; 13: 321-337.
22. Cesari M., Rossi G.P., Pessina A.C.: Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J. Hypertens. 2002; 20: 793-799.
23. Inaba S., Iwai M., Furuno M. et al.: Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009; 53: 356-362.
24. Kolsch H., Jessen F., Freymann N. et al.: ACE I/D polymorphism is a risk factor of Alzheimer`s disease but not of vascular dementia. Neurosci. Lett. 2005; 377: 37-39.
25. Miners J.S., Ashby E., Van Helmond Z. et al.: Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer`s disease, and relationship of perivascular ACE-I to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2008; 34: 181-193.
26. Savaskan E., Hock C., Olivieri G. et al.: Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer`s dementia. Neurobiol. Aging 2001; 22: 541-546.
27. Albiston A.L., McDowall S.G., Matsacos D. et al.: Evidence that the angiote nsin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001; 276: 48623-48626.
28. Yamada K., Horita T., Takayama M. et al.: Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res. 2011; 1421: 110-120.
29. Yamada K., Uchida S., Takahashi S. et al.: Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer`s disease. Brain Res. 2010; 1352: 176-186.
30. Braszko J.J.: Participation of D 1-4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe 6 angiotensin IV. Neurosci. Biobehav. Rev. 2010; 34: 343-350.
31. Braszko J.J.: (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats. Eur. Neuropsychopharmacol. 2010; 20: 218-225.
32. Gard P.R., Olivier G., Golding B. et al.: Assessment of biological activity of novel peptide analogues of angiotensin IV. J. Pharm. Pharmacol. 2011; 63: 565-571.
33. Gałecki P., Szulc A.: Psychiatria. Podręcznik do LEK. Edra 2018.
34. Iadecola C., Yaffe K., Biller J. et al.: Impact of Hypertension on Cognitive Function. Hypertension 2016; 68: e67-e94.
35. Perotta M., Lembo G., Carnevale D.: Hypertension and Dementia: Epidemiological and Experimental Evidence Revealing a Detrimental relationship. Int. J. Mol. Sci. 2016; 17: 347.
36. Gugała M., Łojek E., Lipczyńska-Łojkowska W. et al.: Przegląd metod neuropsychologicznych służących do diagnozy łagodnych zaburzeń poznawczych. Postępy Psychiatrii i Neurologii 2007; 16: 81-85.
37. Mosiołek A.: Metody badań funkcji poznawczych. Psychiatria 2014; 11: 215-221.
38. Raji C.A., Merrill D.A., Eyre H. et al.: Longitudinal Relationships between Caloric Expenditure and Gray Matter in the Cardiovascular Health Study. Journal of Alzheimer’s Disease 2016; 52: 719-729.
39. Rajtar A., Przewoźnik D., Bober-Płonka B. et al.: Montrealski Test do Oceny Funkcji Poznawczych (MoCA) versus Krótka Skala Oceny Stanu Umysłowego (MMSE) – porównanie skuteczności testów w wykrywaniu zaburzeń poznawczych u chorych po udarze mózgu. Geriatria 2014; 8: 5-12.
40. Bilikiewicz A., Matkowska-Białko D.: Zaburzenia funkcji poznawczych a depresja. Udar Mózgu 2004; 6: 27-37.
41. Hess N.C.L., Smart N.A.: Isometric Exercise Training for Managing Vascular risk Factors in Mild Cognitive Impairment and Alzheimer’s Disease. Frontiers in Aging Neuroscience 2017; 9: 68.
42. Długosz-Mazur E., Bojar I., Gustaw K.: Niefarmakologiczne metody postępowania u chorych z otępieniem. Medycyna Ogólna i Nauki o Zdrowiu 2013; 19: 458-462.
43. Jacka F.N., Cherubin N., Anstey K.J. et al.: Western diet is associated with a smaller hippocampus: a longitudinal investigation. BMC Medicine 2015; 13: 215.
44. Magierski R., Antczak-Domagała K., Sobów T.: Dieta jako czynnik protekcyjny otępienia. Aktualn. Neurol. 2014; 14: 167-174.
45. Kiejna A., Pacen P., Trypka E. et al.: Standardy leczenia otępień. Psychogeriatria Polska 2008; 5: 59-94.
46. Michel J.P.: Is it possible to delay or prevent age-related cognitive decline? KJFM 2016; 37: 263-266.
47. Kiss B., Karpati E.: [Mechanism of action of vinpocetine]. Acta Pharm. Hung. 1996; 66: 213-224.
48. Shibota M., Kakihana M., Nagaoka A.: [The effect of vinpocetine on the brain glucose uptake in mice]. Nihon Yakurigaku Zasshi 1982; 80: 221-224.
49. Kakihana M., Suno M., Hamajo K. et al.: [Protective effect of vinpocetine on experimental brain ischemia]. Nihon Yakurigaku Zasshi 1982; 80: 225-229.
50. Kárpáti E., Szporny L.: General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1908-1912.
51. Mchedlishvili G.I., Ormotsadze L.G.: The effect of ethyl apovincaminate on vasospasm of the circulatory isolated internal carotid artery in dogs. Arzneimittelforschung 1981; 31(3): 414-418.
52. van Staveren W.C., Markerink-Vanittersum M., Steinbusch H.W., De Vente J.: The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 2001; 888: 275-286.
53. Sitges M., Galvan E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int. 2005; 46: 533-540.
54. Osawa M., Maruyama S.: Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther. Hung. 1985; 33: 7-12.
55. Gabryel B., Adamek M., Pudełko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
56. Horvath B., Marton Z., Halmosi R. et al.: In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin. Neuropharmacol. 2002; 25: 37-42.
57. Tárnok K., Kiss E., Luiten P.G. et al.: Effects of vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
58. Jeon K.I., Xu X., Aizawa T. et al.: Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
59. Wu L.R., Liu L., Xiong X.Y. et al.: Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget 2017; 8: 80315-80324.
60. Gulyás B., Halldin C., Sóvágó J. et al.: Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging 2002; 29: 1031-1038.
61. Gulyás B., Halldin C., Sandell J. et al.: PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol. Scand. 2002; 106: 325-332.
62. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26(10a): 1984-1989.
63. Werner J., Apecechea M., Schaltenbrand R., Fenz E.: Efficacy and tolerance of vinpocetine administered intravenously, in addition to standard therapy, to patients suffering from an apoplectic insult. W: Krieglstein J. (red.): Pharmacology of cerebral ischemia: proceedings of the International Symposium on Pharmacology of Cerebral Ischemia, held in Marburg (FRG) on 16-17 July 1986. Elsevier Science Publishers, Amsterdam– New York 1986.
64. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
65. Manconi E., Binaghi E., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-709.
66. Valikovics A., Csányi A., Németh L.: [Study of the effects of vinpocetin on cognitive functions]. Ideggyogy Sz. 2012; 65: 115-120.
67. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; (1): CD003119.
68. Charakterystyka produktu leczniczego: CAVINTON Forte, 10 mg, 2017.11.17.
69. Ravaglia G., Forti P., Montesi F. et al.: Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. J. Am. Geriatr. Soc. 2008; 56: 51-58.
70. Kumar R., Dear K.B., Christensen H. et al.: Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: Personality and Total Health through Life 60+ Study. Dement. Geriatr. Cogn. Disord. 2005; 19: 67-74.
71. Sitek E.J., Senderecka M., Nowicka-Sauer K.: Metody przesiewowej oceny funkcji poznawczych w praktyce lekarza rodzinnego. Gabinet Prywatny 2016; 23(4): 49-59.
72. Brodaty H., Pond D., Kemp N.M. et al.: The GPCOG: A new screening test for dementia designed for general pracitce. J. Am. Geriatr. Soc. 2002; 50(3): 530-534.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
3. Zdrojewski T., Rutkowski M., Bandosz P. et al.: Prevalence and control of cardiovascular risk factors in Poland. Assumption and objectives of the NATPOL 2011 Survey. Kardiol. Pol. 2013; 71: 381-391.
4. Zdrojewski T., Szpakowski P., Bandosz P. et al.: Arterial hypertension in Poland in 2002. J. Hum. Hypertens. 2004; 18(8): 557-562.
5. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
6. Tykarski A., Narkiewicz K., Gaciong Z. et al.: 2015 Guidelines for the management of hypertension. Arterial Hypertens. 2015; 19 (2): 53-83.
7. Drygas W., Niklas A., Piwońska A.: Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol. Pol. 2016; 74: 681-690.
8. Ivan C.S., Seshadri S., Beiser A. et al.: Dementia after stroke: the Framingham Study. Stroke 2004; 35: 1264-1268.
9. Wong T.Y., Klein R., Sharrett A.R. et al.: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons. The Atherosclerosis Risk in Communities Study. Stroke 2002; 33: 1487-1492.
10. Vermeer S.E., Longstreth W.T. Jr, Koudstaal P.J.: Silent brain infarcts: a systematic review. Lancet Neurol. 2007; 6(7): 611-619.
11. Fang M., Feng C., Xu Y. et al.: Microbleeds and Silent Brain Infarctions Are Differently Associated with Cognitive Dysfunction in Patients with Advanced Periventricular Leukoaraiosis. Int. J. Med. Sci. 2013; 10(10): 1307-1313.
12. Prabhakaran S., Wright C.B., Yoshita M. et al.: The prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study; Neurology 2008; 70(6): 425-430.
13. Sacco R.L., Adams R., Albers G. et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
14. Baumgart M., Snyder H.M., Carrillo M.C. et al.: Summary of the evidence on modifiable risk factors for cognitive decline and dementia. A population- based perspective. Alzheimers Dement. 2015; 11: 718-726.
15. Skoog I., Lernfelt B., Landahi S. et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347(9009): 1141-1145.
16. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
17. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline does age make a difference? Hypertension 2004; 44: 631-638.
18. Cuadra A.E., Shan Z., Sumners C. et al.: A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol. Ther. 2010; 125: 27-38.
19. Xia H., Lazartigues E.: Angiotensin-converting enzyme 2: central regular for cardiovascular function. Curr. Hypertens. Rep. 2010; 12: 170-175.
20. Wright J.W., Harding J.W.: Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 1997; 25: 96-124.
21. Stragier B., DeBundel D., Sarre S. et al.: Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail. Rev. 2008; 13: 321-337.
22. Cesari M., Rossi G.P., Pessina A.C.: Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J. Hypertens. 2002; 20: 793-799.
23. Inaba S., Iwai M., Furuno M. et al.: Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009; 53: 356-362.
24. Kolsch H., Jessen F., Freymann N. et al.: ACE I/D polymorphism is a risk factor of Alzheimer`s disease but not of vascular dementia. Neurosci. Lett. 2005; 377: 37-39.
25. Miners J.S., Ashby E., Van Helmond Z. et al.: Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer`s disease, and relationship of perivascular ACE-I to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2008; 34: 181-193.
26. Savaskan E., Hock C., Olivieri G. et al.: Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer`s dementia. Neurobiol. Aging 2001; 22: 541-546.
27. Albiston A.L., McDowall S.G., Matsacos D. et al.: Evidence that the angiote nsin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001; 276: 48623-48626.
28. Yamada K., Horita T., Takayama M. et al.: Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res. 2011; 1421: 110-120.
29. Yamada K., Uchida S., Takahashi S. et al.: Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer`s disease. Brain Res. 2010; 1352: 176-186.
30. Braszko J.J.: Participation of D 1-4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe 6 angiotensin IV. Neurosci. Biobehav. Rev. 2010; 34: 343-350.
31. Braszko J.J.: (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats. Eur. Neuropsychopharmacol. 2010; 20: 218-225.
32. Gard P.R., Olivier G., Golding B. et al.: Assessment of biological activity of novel peptide analogues of angiotensin IV. J. Pharm. Pharmacol. 2011; 63: 565-571.
33. Gałecki P., Szulc A.: Psychiatria. Podręcznik do LEK. Edra 2018.
34. Iadecola C., Yaffe K., Biller J. et al.: Impact of Hypertension on Cognitive Function. Hypertension 2016; 68: e67-e94.
35. Perotta M., Lembo G., Carnevale D.: Hypertension and Dementia: Epidemiological and Experimental Evidence Revealing a Detrimental relationship. Int. J. Mol. Sci. 2016; 17: 347.
36. Gugała M., Łojek E., Lipczyńska-Łojkowska W. et al.: Przegląd metod neuropsychologicznych służących do diagnozy łagodnych zaburzeń poznawczych. Postępy Psychiatrii i Neurologii 2007; 16: 81-85.
37. Mosiołek A.: Metody badań funkcji poznawczych. Psychiatria 2014; 11: 215-221.
38. Raji C.A., Merrill D.A., Eyre H. et al.: Longitudinal Relationships between Caloric Expenditure and Gray Matter in the Cardiovascular Health Study. Journal of Alzheimer’s Disease 2016; 52: 719-729.
39. Rajtar A., Przewoźnik D., Bober-Płonka B. et al.: Montrealski Test do Oceny Funkcji Poznawczych (MoCA) versus Krótka Skala Oceny Stanu Umysłowego (MMSE) – porównanie skuteczności testów w wykrywaniu zaburzeń poznawczych u chorych po udarze mózgu. Geriatria 2014; 8: 5-12.
40. Bilikiewicz A., Matkowska-Białko D.: Zaburzenia funkcji poznawczych a depresja. Udar Mózgu 2004; 6: 27-37.
41. Hess N.C.L., Smart N.A.: Isometric Exercise Training for Managing Vascular risk Factors in Mild Cognitive Impairment and Alzheimer’s Disease. Frontiers in Aging Neuroscience 2017; 9: 68.
42. Długosz-Mazur E., Bojar I., Gustaw K.: Niefarmakologiczne metody postępowania u chorych z otępieniem. Medycyna Ogólna i Nauki o Zdrowiu 2013; 19: 458-462.
43. Jacka F.N., Cherubin N., Anstey K.J. et al.: Western diet is associated with a smaller hippocampus: a longitudinal investigation. BMC Medicine 2015; 13: 215.
44. Magierski R., Antczak-Domagała K., Sobów T.: Dieta jako czynnik protekcyjny otępienia. Aktualn. Neurol. 2014; 14: 167-174.
45. Kiejna A., Pacen P., Trypka E. et al.: Standardy leczenia otępień. Psychogeriatria Polska 2008; 5: 59-94.
46. Michel J.P.: Is it possible to delay or prevent age-related cognitive decline? KJFM 2016; 37: 263-266.
47. Kiss B., Karpati E.: [Mechanism of action of vinpocetine]. Acta Pharm. Hung. 1996; 66: 213-224.
48. Shibota M., Kakihana M., Nagaoka A.: [The effect of vinpocetine on the brain glucose uptake in mice]. Nihon Yakurigaku Zasshi 1982; 80: 221-224.
49. Kakihana M., Suno M., Hamajo K. et al.: [Protective effect of vinpocetine on experimental brain ischemia]. Nihon Yakurigaku Zasshi 1982; 80: 225-229.
50. Kárpáti E., Szporny L.: General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1908-1912.
51. Mchedlishvili G.I., Ormotsadze L.G.: The effect of ethyl apovincaminate on vasospasm of the circulatory isolated internal carotid artery in dogs. Arzneimittelforschung 1981; 31(3): 414-418.
52. van Staveren W.C., Markerink-Vanittersum M., Steinbusch H.W., De Vente J.: The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 2001; 888: 275-286.
53. Sitges M., Galvan E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int. 2005; 46: 533-540.
54. Osawa M., Maruyama S.: Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther. Hung. 1985; 33: 7-12.
55. Gabryel B., Adamek M., Pudełko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
56. Horvath B., Marton Z., Halmosi R. et al.: In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin. Neuropharmacol. 2002; 25: 37-42.
57. Tárnok K., Kiss E., Luiten P.G. et al.: Effects of vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008; 53: 289-295.
58. Jeon K.I., Xu X., Aizawa T. et al.: Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
59. Wu L.R., Liu L., Xiong X.Y. et al.: Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling. Oncotarget 2017; 8: 80315-80324.
60. Gulyás B., Halldin C., Sóvágó J. et al.: Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging 2002; 29: 1031-1038.
61. Gulyás B., Halldin C., Sandell J. et al.: PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol. Scand. 2002; 106: 325-332.
62. Szobor A., Klein M.: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung 1976; 26(10a): 1984-1989.
63. Werner J., Apecechea M., Schaltenbrand R., Fenz E.: Efficacy and tolerance of vinpocetine administered intravenously, in addition to standard therapy, to patients suffering from an apoplectic insult. W: Krieglstein J. (red.): Pharmacology of cerebral ischemia: proceedings of the International Symposium on Pharmacology of Cerebral Ischemia, held in Marburg (FRG) on 16-17 July 1986. Elsevier Science Publishers, Amsterdam– New York 1986.
64. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
65. Manconi E., Binaghi E., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-709.
66. Valikovics A., Csányi A., Németh L.: [Study of the effects of vinpocetin on cognitive functions]. Ideggyogy Sz. 2012; 65: 115-120.
67. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003; (1): CD003119.
68. Charakterystyka produktu leczniczego: CAVINTON Forte, 10 mg, 2017.11.17.
69. Ravaglia G., Forti P., Montesi F. et al.: Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. J. Am. Geriatr. Soc. 2008; 56: 51-58.
70. Kumar R., Dear K.B., Christensen H. et al.: Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: Personality and Total Health through Life 60+ Study. Dement. Geriatr. Cogn. Disord. 2005; 19: 67-74.
71. Sitek E.J., Senderecka M., Nowicka-Sauer K.: Metody przesiewowej oceny funkcji poznawczych w praktyce lekarza rodzinnego. Gabinet Prywatny 2016; 23(4): 49-59.
72. Brodaty H., Pond D., Kemp N.M. et al.: The GPCOG: A new screening test for dementia designed for general pracitce. J. Am. Geriatr. Soc. 2002; 50(3): 530-534.